New developments in immunotherapy for SCLC
Small cell lung cancer (SCLC) is an aggressive form of neuroendocrine neoplasm known for its striking initial response to treatment, followed by fast relapse and refractoriness in response to additional lines of therapy. New advances in immunotherapy are paving the way for more effective treatment s...
Saved in:
Main Authors: | Zhonglin Hao, Tsering Dolkar, Christopher Gates, Reinhold Munker |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/1/e009667.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
by: Laura Moliner, MD, et al.
Published: (2025-01-01) -
Assessment of targets of antibody drug conjugates in SCLC
by: Abhishek Ajay, et al.
Published: (2025-01-01) -
Autophagic flux modulates tumor heterogeneity and lineage plasticity in SCLC
by: Yujie Hao, et al.
Published: (2025-01-01) -
Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients
by: Xiaoli Mu, et al.
Published: (2024-09-01) -
Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC
by: Evgenia Taranova, et al.
Published: (2025-01-01)